Trimebutine - NDSRI's



  1.  Torossian, Dieran R.; Aubard, Gilbert G., Preparation of esters of amino alcohols, GB1342547A, Jan 3, 1974, Jouveinal S. A. (
  2. Joo, Eun-Hee; Chang, Woo-Ik; Oh, Injoon; Shin, Sang-Chul; Na, Han-Kwang; Lee, Yong-Bok, High-performance liquid chromatographic determination of trimebutine and its major metabolite, N-monodesmethyl trimebutine, in rat and human plasma, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 723, Issue: 1 + 2, Pages: 239-246, 1999 DOI: (10.1016/s0378-4347(98)00516-7)

Frequently Asked Questions

Nitrosamine impurities have the potential to cause cancer. And so, it is necessary to eliminate nitrosamine impurities in drugs.

Reversed-phase High-performance liquid chromatography (RP-HPLC) helps identify Trimebutine impurities.

The presence of Trimebutine impurities in drugs can lengthen the drug process, impact shelf life, and cause unknown health risks to patients.

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart